CLYM
Climb Bio, Inc. Common StockCLYM
CLYM
About: Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
Employees: 18
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 23
5% less funds holding
Funds holding: 80 [Q4 2024] → 76 (-4) [Q1 2025]
5.9% less ownership
Funds ownership: 82.87% [Q4 2024] → 76.97% (-5.9%) [Q1 2025]
21% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 14
37% less capital invested
Capital invested by funds: $100M [Q4 2024] → $63.4M (-$36.9M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$10
694%
upside
Avg. target
$10
694%
upside
High target
$10
694%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Oppenheimer Leland Gershell | 694%upside $10 | Outperform Initiated | 6 Jun 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that the Company has granted an inducement equity award to a new employee, pursuant to the Company's 2025 Inducement Plan, as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) on Track to Initiate in 2025 CLYM116 Progressing Towards Anticipated IND or CTA Submission in Second Half 2025 Appointed Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors and Perrin Wilson, Ph.D., as Chief Business Officer Strong Financial Position, with Cash Runway Expected Through 2027 WELLESLEY HILLS, Mass.
Neutral
GlobeNewsWire
2 months ago
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors.
Neutral
GlobeNewsWire
2 months ago
Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference
WELLESLEY, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the 24th Annual Needham Healthcare Conference being held virtually April 7-10, 2025.
Neutral
GlobeNewsWire
2 months ago
Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates
Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE)
Neutral
GlobeNewsWire
3 months ago
Climb Bio to Present at Upcoming Investor Conferences
WELLESLEY, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate in the upcoming investor conferences detailed below.
Neutral
GlobeNewsWire
3 months ago
Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer
WELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished leader, with over 17 years of experience in the pharmaceutical and biotech industry.
Neutral
GlobeNewsWire
4 months ago
Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
WELLESLEY, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held virtually February 11-12, 2025.
Neutral
GlobeNewsWire
5 months ago
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
Transaction Expands Climb Bio's Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically Designed to Address Patient Needs Preclinical Data Expected to be Shared Later in 2025 WELLESLEY HILLS, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced it has entered into an exclusive license agreement with Beijing Mabworks Biotech Co., Ltd.
Neutral
PRNewsWire
5 months ago
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Climb Bio, Inc. (NASDAQ: CLYM)
NEW YORK , Jan. 2, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Climb Bio, Inc. (NASDAQ: CLYM) on behalf of the company's shareholders. The investigation seeks to determine whether Climb Bio's directors breached their fiduciary duties in connection with recent corporate actions.
Charts implemented using Lightweight Charts™